• LAST PRICE
    16.8000
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-0.2967%)
  • Bid / Lots
    16.8000/ 2
  • Ask / Lots
    17.8800/ 5
  • Open / Previous Close
    16.9300 / 16.8500
  • Day Range
    Low 16.6900
    High 17.0500
  • 52 Week Range
    Low 10.6800
    High 20.7300
  • Volume
    62,060
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Mar 27, 2024

      Show headlines and story abstract
    • 8:00PM ET on Wednesday Mar 27, 2024 by GlobeNewswire
      Companies Mentioned: HCM
    • 8:00PM ET on Wednesday Mar 27, 2024 by Dow Jones
      Companies Mentioned: HCM

      CONTACTS
      Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries +44 20 3727 1030 / +44 7771 913 902 Ben Atwell / Alex Shaw, FTI (Mobile) / +44 7779 545 055 (Mobile) / Consulting HUTCHMED@fticonsulting.com +852 9783 6894 (Mobile) / Zhou Yi, Brunswick HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon +44 (20) 7886 2500 ____________________ REFERENCES (1) World Health Organization. International Agency for Research on Cancer. All cancers fact sheet. Available at: https://gco.iarc.fr/today/SHYdata/factsheets/cancers/39-All-c ancers-fact-sheet.pdf. Accessed November 2022. ------------------------------------------------------------------------ (2) American Cancer Society. What is Lung Cancer? Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed November 2022. ------------------------------------------------------------------------ (3) Knight SB, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070. (4) Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27. (5) Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48). (6) Szumera-Cieckiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in 11. Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12. (7) Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074). (8) Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of Hematology & Oncology. 2019;63. (9) Vuong HG, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer -- A systematic review and meta-analysis. Lung Cancer 2018; 123: 76-82. (10) Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. (11) Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640. (12) Hartmaier R, et al. Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer Res 15 June 2022; 82 (12_Supplement): LB078. (13) Piotrowska, et al. MET amplification (amp) as a resistance mechanism to osimertinib. Journal of Clinical Oncology 2017 35:15_suppl, 9020-9020. (14) Hartmaier, et al. Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study. Cancer Res (2019) 79 (13_Supplement): 4897. (15) Coleman N, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2019;6(6).
  • Mar 22, 2024

Peers Headlines